Switch to:
Also traded in: Germany, Japan

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
NAS:MNOV's Cash to Debt is ranked higher than
91% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: 46.43 vs. NAS:MNOV: No Debt )
Ranked among companies with meaningful Cash to Debt only.
NAS:MNOV' s Cash to Debt Range Over the Past 10 Years
Min: 0.67  Med: No Debt Max: No Debt
Current: No Debt
Interest Coverage No Debt
NAS:MNOV's Interest Coverage is ranked higher than
87% of the 458 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:MNOV: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:MNOV' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
F-Score: 2
Z-Score: 17.27
M-Score: -3.84
WACC vs ROIC
1.40%
-111.18%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -33.82
NAS:MNOV's ROE (%) is ranked higher than
50% of the 878 Companies
in the Global Biotechnology industry.

( Industry Median: -33.45 vs. NAS:MNOV: -33.82 )
Ranked among companies with meaningful ROE (%) only.
NAS:MNOV' s ROE (%) Range Over the Past 10 Years
Min: -73.58  Med: -42.52 Max: -19.99
Current: -33.82
-73.58
-19.99
ROA (%) -29.71
NAS:MNOV's ROA (%) is ranked higher than
50% of the 971 Companies
in the Global Biotechnology industry.

( Industry Median: -29.51 vs. NAS:MNOV: -29.71 )
Ranked among companies with meaningful ROA (%) only.
NAS:MNOV' s ROA (%) Range Over the Past 10 Years
Min: -52.77  Med: -30.28 Max: -16.41
Current: -29.71
-52.77
-16.41
ROC (Joel Greenblatt) (%) -27095.56
NAS:MNOV's ROC (Joel Greenblatt) (%) is ranked lower than
94% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: -372.06 vs. NAS:MNOV: -27095.56 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:MNOV' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -27190.77  Med: -4249.79 Max: -109.01
Current: -27095.56
-27190.77
-109.01
Revenue Growth (3Y)(%) -100.00
NAS:MNOV's Revenue Growth (3Y)(%) is ranked lower than
96% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. NAS:MNOV: -100.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:MNOV' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0 Max: -100
Current: -100
EBITDA Growth (3Y)(%) -20.40
NAS:MNOV's EBITDA Growth (3Y)(%) is ranked lower than
72% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. NAS:MNOV: -20.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:MNOV' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -83.3  Med: -27.9 Max: 188.9
Current: -20.4
-83.3
188.9
EPS Growth (3Y)(%) -20.60
NAS:MNOV's EPS Growth (3Y)(%) is ranked lower than
69% of the 511 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. NAS:MNOV: -20.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:MNOV' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -86.2  Med: -26.85 Max: 254
Current: -20.6
-86.2
254
» NAS:MNOV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

MNOV Guru Trades in Q4 2015

Jim Simons 98,200 sh (-4.75%)
» More
Q1 2016

MNOV Guru Trades in Q1 2016

Jim Simons 100,100 sh (+1.93%)
» More
Q2 2016

MNOV Guru Trades in Q2 2016

Jim Simons 34,500 sh (-65.53%)
» More
Q3 2016

MNOV Guru Trades in Q3 2016

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with MNOV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NYSE:KDMN, NAS:SGMO, NAS:CMRX, NAS:MRUS, NAS:STML, AMEX:PFNX, NAS:MNKD, NAS:ESPR, NAS:CARA, AMEX:AST, NAS:IDRA, NAS:MDGN, NAS:CNCE, NAS:RXDX, NAS:ABEO, OTCPK:CLVLF, NAS:ARWR, NAS:PETX, AMEX:PIP, NAS:ARGS » details
Traded in other countries:RMN.Germany, 4875.Japan,
MediciNova Inc is a biopharmaceutical company. It is engaged in acquiring and developing small molecule therapeutics for the treatment of serious diseases with unmet medical needs.

MediciNova Inc was incorporated in the State of Delaware in September 2000.It is a biopharmaceutical company focused on developing novel, small molecule therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the U.S. market. The Company operates in a single operating segment - the acquisition and development of small molecule therapeutics for the treatment of serious diseases with unmet medical needs. The Company currently focuses its development activities on MN-166 (ibudilast) for neurological disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and substance dependence (e.g.,methamphetamine dependence, opioid dependence, and alcohol dependence), and MN-001 (tipelukast) for fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). Its pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers.

Ratios

vs
industry
vs
history
P/B 6.91
MNOV's P/B is ranked lower than
75% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. MNOV: 6.91 )
Ranked among companies with meaningful P/B only.
MNOV' s P/B Range Over the Past 10 Years
Min: 0.18  Med: 1.25 Max: 9.45
Current: 6.91
0.18
9.45
Current Ratio 18.63
MNOV's Current Ratio is ranked higher than
91% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. MNOV: 18.63 )
Ranked among companies with meaningful Current Ratio only.
MNOV' s Current Ratio Range Over the Past 10 Years
Min: 1.31  Med: 10.23 Max: 49.29
Current: 18.63
1.31
49.29
Quick Ratio 18.63
MNOV's Quick Ratio is ranked higher than
91% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.94 vs. MNOV: 18.63 )
Ranked among companies with meaningful Quick Ratio only.
MNOV' s Quick Ratio Range Over the Past 10 Years
Min: 1.31  Med: 10.23 Max: 49.29
Current: 18.63
1.31
49.29

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -19.90
MNOV's 3-Year Average Share Buyback Ratio is ranked lower than
67% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. MNOV: -19.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MNOV' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -520.6  Med: -13.9 Max: 0
Current: -19.9
-520.6
0

Valuation & Return

vs
industry
vs
history
Price/Net Cash 12.36
MNOV's Price/Net Cash is ranked lower than
70% of the 518 Companies
in the Global Biotechnology industry.

( Industry Median: 6.05 vs. MNOV: 12.36 )
Ranked among companies with meaningful Price/Net Cash only.
MNOV' s Price/Net Cash Range Over the Past 10 Years
Min: 0.62  Med: 5.57 Max: 30.33
Current: 12.36
0.62
30.33
Price/Net Current Asset Value 11.95
MNOV's Price/Net Current Asset Value is ranked lower than
74% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 5.53 vs. MNOV: 11.95 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
MNOV' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.61  Med: 4.65 Max: 20.79
Current: 11.95
0.61
20.79
Price/Tangible Book 11.56
MNOV's Price/Tangible Book is ranked lower than
81% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. MNOV: 11.56 )
Ranked among companies with meaningful Price/Tangible Book only.
MNOV' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.4  Med: 4.03 Max: 60.74
Current: 11.56
0.4
60.74
Earnings Yield (Greenblatt) (%) -5.45
MNOV's Earnings Yield (Greenblatt) (%) is ranked higher than
56% of the 942 Companies
in the Global Biotechnology industry.

( Industry Median: -8.50 vs. MNOV: -5.45 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MNOV' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -5.63  Med: 98.1 Max: 8448.3
Current: -5.45
-5.63
8448.3

More Statistics

EPS (TTM) $ -0.38
Beta-0.13
Short Percentage of Float9.07%
52-Week Range $3.28 - 10.16
Shares Outstanding (Mil)34.49
» More Articles for NAS:MNOV

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
MediciNova Announces Exploratory Interim Clinical Outcomes Data from Clinical Trial of MN-166... Dec 09 2016
6:00 am MediciNova announces exploratory interim clinical outcomes data from clinical trial of... Dec 09 2016
MediciNova to Present at the Piper Jaffray Healthcare Conference in New York Nov 14 2016
MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Nov 10 2016
MediciNova Announces European Medicines Agency Recommends Orphan Medicinal Product Designation for... Nov 10 2016
MediciNova Announces European Medicines Agency Recommends Orphan Medicinal Product Designation for... Nov 10 2016
MediciNova to Attend Global Mizuho Investor Conference in New York Nov 07 2016
MediciNova to Attend Global Mizuho Investor Conference in New York Nov 07 2016
MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 27th... Oct 30 2016
MEDICINOVA INC Financials Oct 29 2016
MNOV: Interim Analysis of MN-166 in Progressive MS in 4Q16; ODD granted to MN-166 for ALS Oct 27 2016
MediciNova reports 3Q loss Oct 26 2016
MediciNova reports 3Q loss Oct 26 2016
MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure Oct 26 2016
MEDICINOVA INC Files SEC form 10-Q, Quarterly Report Oct 25 2016
MediciNova Announces FDA Granted Orphan Drug Designation to MN-166 (ibudilast) for Amyotrophic... Oct 12 2016
MediciNova Announces FDA Granted Orphan Drug Designation to MN-166 (ibudilast) for Amyotrophic... Oct 11 2016
MediciNova, Inc. :MNOV-US: Earnings Analysis: Q2, 2016 By the Numbers : October 11, 2016 Oct 11 2016
Options on MediciNova Common Stock Listed on CBOE Sep 25 2016
Options on MediciNova Common Stock Listed on CBOE Sep 25 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)